Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

December 21, 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

December 11, 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

December 01, 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

August 04, 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

May 07, 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

April 29, 2020

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

April 13, 2020

Neeraj Agarwal, MD, discusses the implications of the PFS2 data from the TITAN trial in metastatic castration-sensitive prostate cancer.

April 09, 2020

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

March 31, 2020

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

March 18, 2020

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

February 27, 2020

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

February 12, 2020

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.

November 04, 2019

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

October 31, 2019

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

October 29, 2019

Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, University of Utah, discusses quality of life (QoL) with apalutamide (Erleada) in the treatment of patients with metastatic castration-sensitive prostate cancer.

October 24, 2019

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

October 23, 2019

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

October 17, 2019

Anna Chalmers, MD, discusses the PACIFIC trial and how its impact continues to change the treatment paradigm in stage III non-small cell lung cancer.

October 14, 2019

Faculty from Huntsman Cancer Institute and Intermountain Healthcare delve into the interesting research efforts being made at their respective institutions.

October 11, 2019

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.